Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

No data on repeated dose toxicity with Acetoguanamine are available. Because of animal welfare reasons a sub-chronic (90 days) study on Acetoguanamine should not be conducted before data on the prenatal developmental toxicity (OECD414) is available. Within this dossier a testing proposal is submitted (see Section 7.8.2 of the dossier).

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available (further information necessary)

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

No data on repeated dose toxicity with Acetoguanamine are available. Because of animal welfare reasons a sub-chronic (90 days) study on Acetoguanamine should not be conducted before data on the prenatal developmental toxicity (OECD414) is available. Within this dossier a testing proposal is submitted (see Section 7.8.2 of the dossier).

Justification for classification or non-classification

No data on repeated dose toxicity with Acetoguanamine are available. Nevertheless there are no conclusive indications for a classification for repeated dose toxicity at this time. Evaluation will be considered based on the outcome of further sub-chronic repeated dose testing.